Please login to the form below

Not currently logged in
Email:
Password:

ramucirumab

This page shows the latest ramucirumab news and features for those working in and with pharma, biotech and healthcare.

Baricitinib delay casts a pall over Lilly's results update

Baricitinib delay casts a pall over Lilly's results update

reliance on older products such as Trulicity (dulaglutide) for diabetes and cancer drug Cyramza (ramucirumab).

Latest news

  • Lilly pitches Cyramza at bladder cancer Lilly pitches Cyramza at bladder cancer

    The US-based pharma group said its RANGE study of Cyramza (ramucirumab) in patients with locally advanced, unresectable or metastatic urothelial carcinoma (mUC) - the most common form of bladder cancer - could

  • Lilly promises solanezumab news in Alzheimer's 'before year-end' Lilly promises solanezumab news in Alzheimer's 'before year-end'

    Among these, diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) both saw solid sales gains that did not however meet analysts' expectations, while lung cancer therapy Cyramza (ramucirumab) fell 12% thanks to

  • Lilly snags first approval for sarcoma drug Lartruvo Lilly snags first approval for sarcoma drug Lartruvo

    Lilly still has patent protection for the blockbuster in the US until 2022, and in the meantime needs Lartruvo and other recent launches such as Cyramza (ramucirumab) and Portrazza (necitumumab) to

  • Lilly planning 20 new launches by 2023 Lilly planning 20 new launches by 2023

    Lechleiter noted that Lilly has launched six new products in the last two years alone - including Cyramza (ramucirumab), diabetes therapies Jardiance (empagliflozin) and Trulicity (dulaglutide) and most recently Taltz (ixekizumab) for

  • Lilly's psoriasis drug Taltz cleared in Europe Lilly's psoriasis drug Taltz cleared in Europe

    Rising sales of new products such as diabetes treatments Trulicity (dulaglutide) and Basaglar (insulin glargine) and Cyramza (ramucirumab) for stomach cancer offset declines for some of Lilly's older brands, notably

More from news
Approximately 10 fully matching, plus 31 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics